Led by Andrew Mumford
Surgical bleeding occurs in approximately a quarter of cardiac surgery patients, yet currently there is no method of identifying who is most at risk. To help turn this around, we will examine biomarkers, which are molecules, genes, or characteristics, to identify which ones can predict severe surgical bleeding.
We will analyse biomarker data from an established group of around 2,500 heart surgery patients, both adults and children. We will then study the biomarkers identified to predict severe bleeding, and test how accurate they are as diagnostic tools.
We will use the results from this analysis to test the optimal dose of Tranexamic acid in patients at high risk of bleeding, building on the evidence that Tranexamic acid can reduce bleeding in certain patients.